The Pharma industry is facing unprecedented change in all business fundamentals. This event will hear from IMS Health consultant, Carolyn Gauntlett who will focus on the 'new normal' for innovative companies and the transformational steps which must be taken throughout the business to ensure success for players who still passionately believe in innovation.
A G E N D A
-Cost containment in mature is the status quo
− Pharmerging markets struggling to balance aspiration and delivery
− Forecasts: A geographical balance
− Bucking the trend: biologics and specialty medicine
− Pipeline for growth
− Will regulators and payers deliver?
− De-risking of portfolios
− The end of the blockbuster era
− Mid-size vs large pharma
Outline for 2013 global Strategic Management Review (SMR)
As the global economy slowly emerges from the financial crisis and subsequent recessions or lower growth, it is possible to detect that the Pharmaceutical industry is facing unprecedented change in all business fundamentals which is not transient but the 'new normal'.
Thus the 2013 SMR, while recognising that sales will continue to grow in low single digits, tackles the impact of deepening regulation and budgetary control on R+D and commercial structure and operations, the growing impact of pre ordained evidence to justify utilisation in areas of unmet medical needs transforming lifecycle management, and the increasing inclusion of patients and carers in decision making processes.
At the same time there are considerable opportunities for those who have focused on unmet medical needs with proven innovations and leading edge commercial strategies whether it is in diabetes, oncology or stroke prevention: in small or large molecules, or novel delivery methods. Interestingly many of these successes are driven by smaller players so the SMR will conclude with a critical assessment of what went wrong for large Pharma and especially if there is any way back.
Places are limited so book your place now to avoid disappointment.
Carolyn holds an MA in Natural Science and a PhD in Organic Chemistry from Cambridge University. She earned a Fulbright fellowship to undertake post-doctoral research in Medicinal Chemistry at Stanford University in the area of HIV eradication. Working as a research chemist in Singapore before beginning her consulting career at OC&C Strategy Consultants in London; Carolyn then joined the Thought Leadership team in IMS Health in October 2011. She has since worked to provide strategic guidance on a range of topis in the pharmaceutical industry, across therapy areas.